NAVB Navidea Biopharmaceuticals, Inc

+0  (11%)
Previous Close 0.46
Open 0.53
Price To book 0.00
Market Cap 79.46M
Shares 155,555,000
Volume 983,679
Short Ratio 11.76
Av. Daily Volume 1,012,790

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved March 13, 2013.
Lymphatic-tissue tracing agent
Phase 3 - seeking partner to continue development
Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)
Approved June 13, 2014.
Head and Neck Cancer
Phase 2 enrolment commenced February 2016
Uterine Cervical Neoplasms
Phase 1/2 initiated February 2017.
Rheumatoid arthritis

Latest News

  1. Navidea Biopharmaceuticals Invited to Present Data at Two Major Upcoming Conferences
  2. ETFs with exposure to Navidea Biopharmaceuticals, Inc. : April 19, 2017
  3. Navidea Biopharmaceuticals, Inc. :NAVB-US: Earnings Analysis: Q4, 2016 By the Numbers : April 4, 2017
  4. Navidea halved losses in 2016, projects positive cash flow in 2017
  5. Navidea reports 4Q loss
  6. Navidea Provides Corporate Update and Reports Full Year 2016 Results
  7. Why Navidea can recover no more than $12M if it wins against ex-lender in court
  8. Navidea closes Lymphoseek sale to Cardinal Health; lender CRG accepts loan payment, drops liens
  9. Navidea Completes Sale of North American Rights of Lymphoseek® to Cardinal Health
  10. Cardinal Health helps Navidea settle lender's payoff – for now
  11. Navidea to Hold Conference Call to Provide Investor Update on Status of Ongoing Corporate Events
  12. Navidea to Present at Upcoming Investor Conference
  13. ETFs with exposure to Navidea Biopharmaceuticals, Inc. : December 29, 2016
  14. Edited Transcript of NAVB earnings conference call or presentation 3-Nov-16 12:30pm GMT
  15. ETFs with exposure to Navidea Biopharmaceuticals, Inc. : November 28, 2016
  16. Navidea Signs Asset Purchase Agreement with Cardinal Health
  17. Navidea Biopharmaceuticals, Inc. :NAVB-US: Earnings Analysis: Q3, 2016 By the Numbers : November 7, 2016